25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Aadi Bioscience Inc
Buy, Hold or Sell?

Let's analyze Aadi Bioscience Inc together

I guess you are interested in Aadi Bioscience Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Aadi Bioscience Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Aadi Bioscience Inc

I send you an email if I find something interesting about Aadi Bioscience Inc.

1. Quick Overview

1.1. Quick analysis of Aadi Bioscience Inc (30 sec.)










1.2. What can you expect buying and holding a share of Aadi Bioscience Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
12.5%

What is your share worth?

Current worth
$2.55
Expected worth in 1 year
$0.71
How sure are you?
22.5%

+ What do you gain per year?

Total Gains per Share
$-1.84
Return On Investment
-77.9%

For what price can you sell your share?

Current Price per Share
$2.36
Expected price per share
$1.8 - $2.45
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Aadi Bioscience Inc (5 min.)




Live pricePrice per Share (EOD)
$2.36
Intrinsic Value Per Share
$-27.48 - $-11.26
Total Value Per Share
$-24.93 - $-8.72

2.2. Growth of Aadi Bioscience Inc (5 min.)




Is Aadi Bioscience Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$68.8m$138.4m-$52.6m-61.4%

How much money is Aadi Bioscience Inc making?

Current yearPrevious yearGrowGrow %
Making money-$15.4m-$15.4m$44.2k0.3%
Net Profit Margin-252.2%-265.7%--

How much money comes from the company's main activities?

2.3. Financial Health of Aadi Bioscience Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Aadi Bioscience Inc?

Welcome investor! Aadi Bioscience Inc's management wants to use your money to grow the business. In return you get a share of Aadi Bioscience Inc.

First you should know what it really means to hold a share of Aadi Bioscience Inc. And how you can make/lose money.

Speculation

The Price per Share of Aadi Bioscience Inc is $2.36. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Aadi Bioscience Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Aadi Bioscience Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.55. Based on the TTM, the Book Value Change Per Share is $-0.46 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.62 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Aadi Bioscience Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.46-19.7%-0.57-24.2%-0.59-25.0%-0.57-24.1%-0.34-14.4%
Usd Book Value Change Per Share-0.37-15.7%-0.46-19.5%-0.62-26.2%0.041.8%0.062.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.041.8%0.020.9%
Usd Total Gains Per Share-0.37-15.7%-0.46-19.5%-0.62-26.2%0.093.7%0.093.6%
Usd Price Per Share2.06-1.97-7.94-7.22-4.28-
Price to Earnings Ratio-1.11--0.87--3.48--2.80--1.97-
Price-to-Total Gains Ratio-5.56--4.34--12.76--4.80--6.09-
Price to Book Ratio0.81-0.63-1.50-1.41-1.43-
Price-to-Total Gains Ratio-5.56--4.34--12.76--4.80--6.09-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.36
Number of shares423
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.04
Usd Book Value Change Per Share-0.460.04
Usd Total Gains Per Share-0.460.09
Gains per Quarter (423 shares)-194.5336.44
Gains per Year (423 shares)-778.12145.77
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-778-7887372136
20-1556-1566147145282
30-2334-2344220217428
40-3112-3122294289574
50-3891-3900367361720
60-4669-4678441434866
70-5447-54565145061012
80-6225-62345885781158
90-7003-70126616501304
100-7781-77907357231450

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%2.038.00.05.0%3.055.00.05.2%
Book Value Change Per Share0.04.00.00.0%1.011.00.08.3%5.015.00.025.0%8.032.00.020.0%8.050.00.013.8%
Dividend per Share0.00.04.00.0%1.00.011.08.3%5.00.015.025.0%5.00.035.012.5%5.00.053.08.6%
Total Gains per Share0.04.00.00.0%1.011.00.08.3%6.014.00.030.0%9.031.00.022.5%9.049.00.015.5%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Aadi Bioscience Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.370-0.460+24%-0.619+67%0.043-967%0.064-680%
Book Value Per Share--2.5473.179-20%5.153-51%3.515-28%2.186+16%
Current Ratio--4.8894.742+3%9.120-46%10.035-51%8.081-39%
Debt To Asset Ratio--0.1960.203-3%0.142+38%0.204-4%5.315-96%
Debt To Equity Ratio--0.2440.255-4%0.166+47%0.139+76%0.111+121%
Dividend Per Share----0%-0%0.043-100%0.022-100%
Eps---0.464-0.571+23%-0.590+27%-0.568+22%-0.340-27%
Free Cash Flow Per Share---0.758-0.565-25%-0.600-21%-0.392-48%-0.241-68%
Free Cash Flow To Equity Per Share---1.658-0.789-52%-0.599-64%0.001-138737%0.085-2041%
Gross Profit Margin--1.0001.0000%1.035-3%1.060-6%1.030-3%
Intrinsic Value_10Y_max---11.264--------
Intrinsic Value_10Y_min---27.481--------
Intrinsic Value_1Y_max---0.989--------
Intrinsic Value_1Y_min---2.347--------
Intrinsic Value_3Y_max---3.077--------
Intrinsic Value_3Y_min---7.447--------
Intrinsic Value_5Y_max---5.295--------
Intrinsic Value_5Y_min---12.938--------
Market Cap58167864.000+4%55705133.62053186430.525+5%213276316.228-74%182473639.572-69%107831298.021-48%
Net Profit Margin---1.740-2.522+45%-2.657+53%-10.207+487%-104.531+5909%
Operating Margin---1.734-2.513+45%-2.934+69%-9.813+466%-104.334+5916%
Operating Ratio--2.9713.735-20%4.023-26%11.320-74%109.217-97%
Pb Ratio0.927+13%0.8090.631+28%1.502-46%1.415-43%1.430-43%
Pe Ratio-1.272-15%-1.110-0.872-21%-3.485+214%-2.797+152%-1.973+78%
Price Per Share2.360+13%2.0601.970+5%7.938-74%7.223-71%4.285-52%
Price To Free Cash Flow Ratio-0.779-15%-0.680-0.943+39%-3.709+446%-3.836+464%-2.552+275%
Price To Total Gains Ratio-6.373-15%-5.563-4.336-22%-12.763+129%-4.802-14%-6.094+10%
Quick Ratio--6.4026.101+5%14.034-54%11.847-46%8.916-28%
Return On Assets---0.146-0.144-1%-0.098-33%-0.140-4%-8.299+5569%
Return On Equity---0.182-0.181-1%-0.114-37%-0.141-22%-0.122-33%
Total Gains Per Share---0.370-0.460+24%-0.619+67%0.086-530%0.086-533%
Usd Book Value--68868000.00085828500.000-20%138494750.000-50%90418341.100-24%55780550.650+23%
Usd Book Value Change Per Share---0.370-0.460+24%-0.619+67%0.043-967%0.064-680%
Usd Book Value Per Share--2.5473.179-20%5.153-51%3.515-28%2.186+16%
Usd Dividend Per Share----0%-0%0.043-100%0.022-100%
Usd Eps---0.464-0.571+23%-0.590+27%-0.568+22%-0.340-27%
Usd Free Cash Flow---20484000.000-15258500.000-26%-16140750.000-21%-10205165.650-50%-6203306.700-70%
Usd Free Cash Flow Per Share---0.758-0.565-25%-0.600-21%-0.392-48%-0.241-68%
Usd Free Cash Flow To Equity Per Share---1.658-0.789-52%-0.599-64%0.001-138737%0.085-2041%
Usd Market Cap58167864.000+4%55705133.62053186430.525+5%213276316.228-74%182473639.572-69%107831298.021-48%
Usd Price Per Share2.360+13%2.0601.970+5%7.938-74%7.223-71%4.285-52%
Usd Profit---12546000.000-15421749.750+23%-15466000.000+23%-15209240.350+21%-8976879.725-28%
Usd Revenue--7212000.0006267500.000+15%5813750.000+24%3693247.150+95%2350559.325+207%
Usd Total Gains Per Share---0.370-0.460+24%-0.619+67%0.086-530%0.086-533%
 EOD+5 -3MRQTTM+19 -14YOY+14 -205Y+10 -2610Y+12 -24

3.3 Fundamental Score

Let's check the fundamental score of Aadi Bioscience Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.272
Price to Book Ratio (EOD)Between0-10.927
Net Profit Margin (MRQ)Greater than0-1.740
Operating Margin (MRQ)Greater than0-1.734
Quick Ratio (MRQ)Greater than16.402
Current Ratio (MRQ)Greater than14.889
Debt to Asset Ratio (MRQ)Less than10.196
Debt to Equity Ratio (MRQ)Less than10.244
Return on Equity (MRQ)Greater than0.15-0.182
Return on Assets (MRQ)Greater than0.05-0.146
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Aadi Bioscience Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5066.793
Ma 20Greater thanMa 502.184
Ma 50Greater thanMa 1002.074
Ma 100Greater thanMa 2001.844
OpenGreater thanClose2.340
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Aadi Bioscience Inc

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Fundamental data was last updated by Penke on 2024-11-25 01:24:02.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Aadi Bioscience Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Aadi Bioscience Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -174.0% means that $-1.74 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Aadi Bioscience Inc:

  • The MRQ is -174.0%. The company is making a huge loss. -2
  • The TTM is -252.2%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-174.0%TTM-252.2%+78.2%
TTM-252.2%YOY-265.7%+13.5%
TTM-252.2%5Y-1,020.7%+768.5%
5Y-1,020.7%10Y-10,453.1%+9,432.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-174.0%-112.2%-61.8%
TTM-252.2%-221.4%-30.8%
YOY-265.7%-210.0%-55.7%
5Y-1,020.7%-342.2%-678.5%
10Y-10,453.1%-464.5%-9,988.6%
4.3.1.2. Return on Assets

Shows how efficient Aadi Bioscience Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Aadi Bioscience Inc to the Biotechnology industry mean.
  • -14.6% Return on Assets means that Aadi Bioscience Inc generated $-0.15 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Aadi Bioscience Inc:

  • The MRQ is -14.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -14.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-14.6%TTM-14.4%-0.2%
TTM-14.4%YOY-9.8%-4.7%
TTM-14.4%5Y-14.0%-0.4%
5Y-14.0%10Y-829.9%+815.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-14.6%-11.3%-3.3%
TTM-14.4%-11.7%-2.7%
YOY-9.8%-11.3%+1.5%
5Y-14.0%-12.7%-1.3%
10Y-829.9%-14.1%-815.8%
4.3.1.3. Return on Equity

Shows how efficient Aadi Bioscience Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Aadi Bioscience Inc to the Biotechnology industry mean.
  • -18.2% Return on Equity means Aadi Bioscience Inc generated $-0.18 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Aadi Bioscience Inc:

  • The MRQ is -18.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -18.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-18.2%TTM-18.1%-0.1%
TTM-18.1%YOY-11.4%-6.7%
TTM-18.1%5Y-14.1%-4.0%
5Y-14.1%10Y-12.2%-1.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-18.2%-14.2%-4.0%
TTM-18.1%-15.9%-2.2%
YOY-11.4%-14.3%+2.9%
5Y-14.1%-18.5%+4.4%
10Y-12.2%-19.3%+7.1%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Aadi Bioscience Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Aadi Bioscience Inc is operating .

  • Measures how much profit Aadi Bioscience Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Aadi Bioscience Inc to the Biotechnology industry mean.
  • An Operating Margin of -173.4% means the company generated $-1.73  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Aadi Bioscience Inc:

  • The MRQ is -173.4%. The company is operating very inefficient. -2
  • The TTM is -251.3%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-173.4%TTM-251.3%+77.9%
TTM-251.3%YOY-293.4%+42.1%
TTM-251.3%5Y-981.3%+730.0%
5Y-981.3%10Y-10,433.4%+9,452.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-173.4%-222.9%+49.5%
TTM-251.3%-310.7%+59.4%
YOY-293.4%-223.5%-69.9%
5Y-981.3%-387.1%-594.2%
10Y-10,433.4%-498.5%-9,934.9%
4.3.2.2. Operating Ratio

Measures how efficient Aadi Bioscience Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 2.97 means that the operating costs are $2.97 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Aadi Bioscience Inc:

  • The MRQ is 2.971. The company is inefficient in keeping operating costs low. -1
  • The TTM is 3.735. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.971TTM3.735-0.763
TTM3.735YOY4.023-0.288
TTM3.7355Y11.320-7.585
5Y11.32010Y109.217-97.897
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.9712.465+0.506
TTM3.7353.253+0.482
YOY4.0233.298+0.725
5Y11.3204.788+6.532
10Y109.2176.494+102.723
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Aadi Bioscience Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Aadi Bioscience Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.89 means the company has $4.89 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Aadi Bioscience Inc:

  • The MRQ is 4.889. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.742. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.889TTM4.742+0.147
TTM4.742YOY9.120-4.378
TTM4.7425Y10.035-5.292
5Y10.03510Y8.081+1.954
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.8893.637+1.252
TTM4.7423.890+0.852
YOY9.1204.666+4.454
5Y10.0355.953+4.082
10Y8.0816.277+1.804
4.4.3.2. Quick Ratio

Measures if Aadi Bioscience Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Aadi Bioscience Inc to the Biotechnology industry mean.
  • A Quick Ratio of 6.40 means the company can pay off $6.40 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Aadi Bioscience Inc:

  • The MRQ is 6.402. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 6.101. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ6.402TTM6.101+0.301
TTM6.101YOY14.034-7.933
TTM6.1015Y11.847-5.746
5Y11.84710Y8.916+2.931
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.4023.086+3.316
TTM6.1013.451+2.650
YOY14.0344.456+9.578
5Y11.8475.931+5.916
10Y8.9166.436+2.480
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Aadi Bioscience Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Aadi Bioscience Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Aadi Bioscience Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.20 means that Aadi Bioscience Inc assets are financed with 19.6% credit (debt) and the remaining percentage (100% - 19.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Aadi Bioscience Inc:

  • The MRQ is 0.196. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.203. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.196TTM0.203-0.007
TTM0.203YOY0.142+0.061
TTM0.2035Y0.204-0.001
5Y0.20410Y5.315-5.111
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1960.350-0.154
TTM0.2030.344-0.141
YOY0.1420.310-0.168
5Y0.2040.365-0.161
10Y5.3150.382+4.933
4.5.4.2. Debt to Equity Ratio

Measures if Aadi Bioscience Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Aadi Bioscience Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 24.4% means that company has $0.24 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Aadi Bioscience Inc:

  • The MRQ is 0.244. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.255. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.244TTM0.255-0.011
TTM0.255YOY0.166+0.089
TTM0.2555Y0.139+0.117
5Y0.13910Y0.111+0.028
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2440.394-0.150
TTM0.2550.432-0.177
YOY0.1660.380-0.214
5Y0.1390.451-0.312
10Y0.1110.490-0.379
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Aadi Bioscience Inc generates.

  • Above 15 is considered overpriced but always compare Aadi Bioscience Inc to the Biotechnology industry mean.
  • A PE ratio of -1.11 means the investor is paying $-1.11 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Aadi Bioscience Inc:

  • The EOD is -1.272. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.110. Based on the earnings, the company is expensive. -2
  • The TTM is -0.872. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.272MRQ-1.110-0.162
MRQ-1.110TTM-0.872-0.238
TTM-0.872YOY-3.485+2.613
TTM-0.8725Y-2.797+1.925
5Y-2.79710Y-1.973-0.824
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.272-2.303+1.031
MRQ-1.110-2.403+1.293
TTM-0.872-3.148+2.276
YOY-3.485-3.251-0.234
5Y-2.797-6.084+3.287
10Y-1.973-6.764+4.791
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Aadi Bioscience Inc:

  • The EOD is -0.779. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.680. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.943. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.779MRQ-0.680-0.099
MRQ-0.680TTM-0.943+0.263
TTM-0.943YOY-3.709+2.766
TTM-0.9435Y-3.836+2.893
5Y-3.83610Y-2.552-1.284
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.779-3.042+2.263
MRQ-0.680-3.234+2.554
TTM-0.943-3.719+2.776
YOY-3.709-4.557+0.848
5Y-3.836-8.332+4.496
10Y-2.552-9.276+6.724
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Aadi Bioscience Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.81 means the investor is paying $0.81 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Aadi Bioscience Inc:

  • The EOD is 0.927. Based on the equity, the company is cheap. +2
  • The MRQ is 0.809. Based on the equity, the company is cheap. +2
  • The TTM is 0.631. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.927MRQ0.809+0.118
MRQ0.809TTM0.631+0.178
TTM0.631YOY1.502-0.871
TTM0.6315Y1.415-0.783
5Y1.41510Y1.430-0.015
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.9271.943-1.016
MRQ0.8092.051-1.242
TTM0.6312.356-1.725
YOY1.5022.454-0.952
5Y1.4153.714-2.299
10Y1.4304.378-2.948
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Aadi Bioscience Inc.

4.8.1. Institutions holding Aadi Bioscience Inc

Institutions are holding 49.06% of the shares of Aadi Bioscience Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30venBio Select Advisor LLC11.5760.0856284940200
2024-09-30BML Capital Management LLC8.12522.4243200000020000000
2024-09-30Longwood Capital Partners LLC7.51343.0857184940200
2024-09-30EcoR1 Capital, LLC7.49650.1301184525318452530
2024-09-30Vanguard Group Inc3.1119076599200
2024-09-30Renaissance Technologies Corp1.87620.0014461822226005.1455
2024-09-30Acuitas Investments, LLC1.78250.4034387608627724.4769
2024-06-30Soleus Capital Management, L.P.1.35380.04293332273332270
2024-06-30BlackRock Inc1.3010320247-720759-69.2368
2024-06-30Millennium Management LLC0.91850.00022260852260850
2024-09-30Geode Capital Management, LLC0.8481020874823051.1165
2024-06-30Goldman Sachs Group Inc0.62670154270104691211.16
2024-06-30Jane Street Group LLC0.545301342341342340
2024-06-30Morgan Stanley - Brokerage Accounts0.52740129808-799124-86.0261
2024-06-30Susquehanna International Group, LLP0.40609993161216158.1196
2024-09-30Bridgeway Capital Management, LLC0.3790.004293300933000
2024-06-30Verition Fund Managegment, LLC0.33460.00078236150166155.8192
2024-06-30UBS Group AG0.285907036549654239.747
2024-06-30State Street Corp0.2793068737-306410-81.6773
2024-09-30Northern Trust Corp0.2782068474-90206-56.8477
Total 49.56556.178112200418+3092509+25.3%

4.9.2. Funds holding Aadi Bioscience Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-10-31Vanguard Total Stock Mkt Idx Inv2.0310.000149992600
2024-10-31Vanguard Institutional Extnd Mkt Idx Tr1.00560.000524752000
2024-09-30Fidelity Extended Market Index0.48630.00061196955020.4212
2024-09-30BlackRock Extended Equity Market K0.17910.000644096-19-0.0431
2024-10-31iShares Micro-Cap ETF0.15580.00853834200
2024-09-30Fidelity Series Total Market Index0.10780.00012652400
2024-09-30Fidelity Total Market Index0.10620.00012613700
2024-09-30Northern Trust Extended Eq Market Idx0.09970.00072453200
2024-09-30NT Ext Equity Mkt Idx Fd - L0.09970.00072453200
2024-09-30NT Ext Equity Mkt Idx Fd - NL0.09160.00072254000
2024-09-30NT Ext Equity Mkt Idx Fd - DC - NL - T20.07380.000718160550.3038
2024-09-30Spartan Extended Market Index Pool E0.05780.000714236142360
2024-10-31Vanguard Balanced Index Inv0.05360.00011320000
2024-09-30Spartan Total Market Index Pool E0.05070.00011247500
2024-03-31Vanguard Instl Ttl Stck Mkt Idx Tr0.0420.00011033700
2024-09-30Vifag 2002 SICAV0.04060.02941000000
2024-09-30Fidelity Nasdaq Composite Index0.03870.0001952800
2024-09-30BlackRock U.S. Equity Market F0.03490.00018599-1-0.0116
2024-10-31State St US Extended Mkt Indx NL Cl C0.03410.0009840000
2024-09-30T. Rowe Price Extended Equity Market Idx0.02750.0014677900
Total 4.81650.04621185558+14773+1.2%

5.3. Insider Transactions

Insiders are holding 9.961% of the shares of Aadi Bioscience Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-10-03David James LennonSELL96891.94
2024-09-03Neil DesaiSELL400001.71
2024-08-05Neil DesaiSELL56521.34
2024-08-01Neil DesaiSELL154151.5
2024-07-01Neil DesaiSELL313481.45
2024-05-01Neil DesaiSELL400001.93
2024-04-01Neil DesaiSELL177722.31
2024-03-04Neil DesaiSELL149642.1
2024-03-01Neil DesaiSELL270361.97
2024-02-01Neil DesaiSELL420001.74
2024-01-02Neil DesaiSELL420002.06
2023-12-06Neil DesaiSELL70374.82
2023-12-04Neil DesaiSELL108765.15
2023-12-01Neil DesaiSELL83475.14
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets85,698
Total Liabilities16,830
Total Stockholder Equity68,868
 As reported
Total Liabilities 16,830
Total Stockholder Equity+ 68,868
Total Assets = 85,698

Assets

Total Assets85,698
Total Current Assets77,315
Long-term Assets8,383
Total Current Assets
Cash And Cash Equivalents 30,537
Short-term Investments 32,082
Net Receivables 6,540
Inventory 5,468
Other Current Assets 2,688
Total Current Assets  (as reported)77,315
Total Current Assets  (calculated)77,315
+/-0
Long-term Assets
Property Plant Equipment 6,868
Long-term Assets Other 1,515
Long-term Assets  (as reported)8,383
Long-term Assets  (calculated)8,383
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities15,813
Long-term Liabilities1,017
Total Stockholder Equity68,868
Total Current Liabilities
Short-term Debt 322
Accounts payable 1,374
Other Current Liabilities 14,117
Total Current Liabilities  (as reported)15,813
Total Current Liabilities  (calculated)15,813
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)1,017
Long-term Liabilities  (calculated)0
+/- 1,017
Total Stockholder Equity
Common Stock2
Retained Earnings -314,381
Accumulated Other Comprehensive Income 39
Other Stockholders Equity 383,208
Total Stockholder Equity (as reported)68,868
Total Stockholder Equity (calculated)68,868
+/-0
Other
Cash and Short Term Investments 62,619
Common Stock Shares Outstanding 27,041
Liabilities and Stockholders Equity 85,698
Net Debt -29,591
Net Working Capital 61,502
Short Long Term Debt Total 946



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-31
> Total Assets 
28
17
12
8
7
21
16
13
11
11
6
29
25
15
11
7
24
16
11
8
4
18
15
9
7
5
18
5
23
10
6
19
13
20
8
4
36,280
29,794
26,002
21,028
14,734
69,539
70,162
64,123
55,057
49,600
45,552
39,937
35,700
45,716
49,830
18,825
41,161
37,424
168,772
157,910
142,319
128,636
194,103
184,237
170,654
151,228
139,659
132,423
111,073
101,620
85,698
85,698101,620111,073132,423139,659151,228170,654184,237194,103128,636142,319157,910168,77237,42441,16118,82549,83045,71635,70039,93745,55249,60055,05764,12370,16269,53914,73421,02826,00229,79436,28048201319610235185791518481116247111525296111113162178121728
   > Total Current Assets 
28
12
9
8
7
17
13
11
11
6
2
27
25
15
11
7
24
16
11
8
4
18
10
6
6
5
18
5
23
10
6
19
13
20
8
4
36,121
29,644
25,864
20,899
14,610
69,426
70,040
63,984
54,299
48,789
44,804
39,570
15,962
45,435
49,583
18,685
40,999
37,395
162,018
151,272
135,620
124,335
189,863
180,029
164,930
144,923
132,884
124,586
102,573
93,005
77,315
77,31593,005102,573124,586132,884144,923164,930180,029189,863124,335135,620151,272162,01837,39540,99918,68549,58345,43515,96239,57044,80448,78954,29963,98470,04069,42614,61020,89925,86429,64436,121482013196102351856610184811162471115252726111113177891228
       Cash And Cash Equivalents 
28
12
9
8
7
17
13
11
11
6
2
27
25
9
6
4
24
9
5
5
3
18
10
6
6
5
18
5
23
10
6
19
13
20
8
4
35,139
28,848
24,829
20,264
13,764
68,783
68,807
62,614
53,423
48,157
43,390
38,525
-15,962
44,864
47,282
4,455
39,009
36,816
161,375
148,989
129,849
118,737
134,815
39,019
34,046
68,162
68,803
62,888
53,780
41,139
30,537
30,53741,13953,78062,88868,80368,16234,04639,019134,815118,737129,849148,989161,37536,81639,0094,45547,28244,864-15,96238,52543,39048,15753,42362,61468,80768,78313,76420,26424,82928,84835,13948201319610235185661018355924469252726111113177891228
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
50
50
50
0
0
0
0
0
0
0
0
0
31,924
0
0
0
0
0
0
0
0
0
48,192
133,541
117,128
66,727
50,532
45,957
34,491
37,429
32,082
32,08237,42934,49145,95750,53266,727117,128133,54148,19200000000031,924000000000505050000000000000000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
32
4
39
0
0
0
0
0
0
0
0
0
0
0
0
14,149
120
0
0
0
2,708
2,063
2,261
1,862
5,565
3,676
5,717
5,488
4,933
5,920
6,540
6,5405,9204,9335,4885,7173,6765,5651,8622,2612,0632,70800012014,14900000000000039432000000000000000000000000000000000000
       Other Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
6
4
3
1
6
6
4
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
900
742
946
635
846
642
1,232
1,370
876
632
1,415
1,046
808
570
2,301
81
1,991
578
643
2,283
2,861
2,808
3,861
3,746
4,388
2,901
4,217
3,826
3,433
2,419
2,688
2,6882,4193,4333,8264,2172,9014,3883,7463,8612,8082,8612,2836435781,991812,3015708081,0461,4156328761,3701,232642846635946742900000000000000000146613460000000000000
   > Long-term Assets 
0
0
0
0
0
0
0
2
0
0
0
3
0
0
0
3
0
0
0
4
0
0
4
3
1
0
0
0
0
0
0
0
0
0
0
0
159
150
138
128
124
113
122
139
758
811
747
366
-15,962
281
247
140
162
29
6,754
6,638
6,699
4,301
4,240
4,208
5,724
6,305
6,775
7,837
8,500
8,615
8,383
8,3838,6158,5007,8376,7756,3055,7244,2084,2404,3016,6996,6386,75429162140247281-15,962366747811758139122113124128138150159000000000001340040003000300020000000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
138
129
117
107
103
92
101
98
717
770
706
326
288
261
227
140
142
9
611
614
619
2,010
2,030
2,030
3,662
4,354
4,861
5,971
6,763
6,986
6,868
6,8686,9866,7635,9714,8614,3543,6622,0302,0302,01061961461191421402272612883267067707179810192103107117129138000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,880
3,811
3,743
0
0
0
0
0
0
0
0
0
0
00000000003,7433,8113,880000000000000000000000000000000000000000000000000000000
       Other Assets 
0
5
3
0
0
5
3
0
0
6
4
0
1
6
4
-3
1
6
6
-4
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
35,700
0
0
206
0
0
168,772
2,213
2,337
2,291
2,210
2,178
0
1,951
0
0
0
0
0
000001,95102,1782,2102,2912,3372,213168,772002060035,7000000000000000000000000000001-4661-3461046003500350
> Total Liabilities 
0
0
0
0
0
27
27
32
34
40
39
70
71
68
70
75
98
95
97
104
105
127
129
133
137
142
161
160
184
178
181
205
206
221
215
230
2,970
1,857
2,586
3,592
3,623
21,632
3,645
5,457
4,261
3,884
3,837
3,401
2,694
3,115
2,512
31,257
2,129
2,208
17,847
21,504
17,691
19,906
24,995
25,859
24,668
19,809
21,463
27,228
20,613
22,829
16,830
16,83022,82920,61327,22821,46319,80924,66825,85924,99519,90617,69121,50417,8472,2082,12931,2572,5123,1152,6943,4013,8373,8844,2615,4573,64521,6323,6233,5922,5861,8572,970230215221206205181178184160161142137133129127105104979598757068717039403432272700000
   > Total Current Liabilities 
0
0
0
0
0
25
25
25
25
35
35
60
60
68
70
75
98
95
97
104
105
127
129
133
137
142
161
160
184
178
181
205
206
221
215
230
2,970
1,857
2,586
3,592
3,623
21,632
3,645
5,457
3,924
3,596
3,601
3,334
2,654
3,105
2,512
30,058
2,129
2,208
11,567
15,273
11,510
12,596
17,891
18,835
17,747
12,996
20,517
26,395
19,875
22,147
15,813
15,81322,14719,87526,39520,51712,99617,74718,83517,89112,59611,51015,27311,5672,2082,12930,0582,5123,1052,6543,3343,6013,5963,9245,4573,64521,6323,6233,5922,5861,8572,970230215221206205181178184160161142137133129127105104979598757068606035352525252500000
       Short-term Debt 
0
0
0
0
0
25
25
25
25
35
35
60
60
60
60
60
85
85
85
85
85
110
110
110
110
110
125
125
145
145
145
160
160
170
170
170
0
0
0
0
0
0
0
0
190
193
197
103
107
111
95
9,154
39
10
90
131
163
324
374
394
404
413
423
434
425
374
322
3223744254344234134043943743241631319010399,15495111107103197193190000000001701701701601601451451451251251101101101101108585858585606060606035352525252500000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,029
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000009,029000000000000000000000000000000000000000000000000000
       Accounts payable 
0
0
0
0
0
0
0
0
0
0
0
0
0
2
3
3
4
0
1
2
6
0
1
0
1
8
11
2
10
2
3
4
8
10
2
4
1,872
782
855
1,277
1,626
1,074
717
596
1,062
511
751
440
421
623
709
2,392
459
747
5,205
6,439
4,010
3,619
3,920
3,519
6,510
2,898
2,605
5,898
3,095
2,265
1,374
1,3742,2653,0955,8982,6052,8986,5103,5193,9203,6194,0106,4395,2057474592,3927096234214407515111,0625967171,0741,6261,2778557821,872421084321021181010621043320000000000000
       Other Current Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
6
7
12
9
10
12
17
14
17
19
23
26
23
26
33
29
31
33
41
38
41
43
56
1,098
1,075
1,731
2,316
1,997
1,892
2,928
4,861
2,672
2,891
2,653
2,792
2,127
2,372
1,708
99
1,631
1,451
6,272
8,703
7,337
8,653
13,597
14,922
10,833
9,685
17,489
20,063
16,355
19,508
14,117
14,11719,50816,35520,06317,4899,68510,83314,92213,5978,6537,3378,7036,2721,4511,631991,7082,3722,1272,7922,6532,8912,6724,8612,9281,8921,9972,3161,7311,0751,09856434138413331293326232623191714171210912760000000000000
   > Long-term Liabilities 
0
0
0
0
0
2
2
7
9
5
4
10
11
60
60
60
85
85
85
85
85
110
110
110
110
110
125
125
145
145
145
41
160
41
43
56
0
0
0
0
0
0
0
0
338
288
236
67
39
10
0
1,199
0
0
6,280
6,231
6,181
7,310
7,104
7,024
6,921
6,813
946
833
738
682
1,017
1,0176827388339466,8136,9217,0247,1047,3106,1816,2316,280001,199010396723628833800000000564341160411451451451251251101101101101108585858585606060111045972200000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
38
0
5,757
5,757
5,757
5,866
5,757
5,757
0
5,757
0
0
0
0
0
000005,75705,7575,7575,8665,7575,7575,7570380000000000000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,656
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000001,65600000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
26
15
11
1
-2
-6
-11
-19
-23
-28
-33
-41
-46
-53
-59
-68
-74
-80
-86
-96
-102
-108
-114
-124
-130
-137
-143
-155
-161
-168
-175
-186
-193
-200
-207
-226
33,310
27,938
23,415
17,435
11,112
47,906
66,517
58,667
50,795
45,716
41,714
36,535
-9,094
42,600
47,318
-12,432
39,032
35,216
150,925
136,406
124,628
108,730
169,108
158,378
145,986
131,419
118,196
105,195
90,460
78,791
68,868
68,86878,79190,460105,195118,196131,419145,986158,378169,108108,730124,628136,406150,92535,21639,032-12,43247,31842,600-9,09436,53541,71445,71650,79558,66766,51747,90611,11217,43523,41527,93833,310-226-207-200-193-186-175-168-161-155-143-137-130-124-114-108-102-96-86-80-74-68-59-53-46-41-33-28-23-19-11-6-21111526
   Common Stock
1
0
1
0
0
1
1
1
1
1
0
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
3
3
3
3
3
4
4
4
4
4
4
4
4
4
5
1
5
5
2
2
2
2
2
2
2
2
2
2
2
2
2
2222222222222551544444444433333111111111111111111111111101111100101
   Retained Earnings -314,381-301,835-287,252-268,963-252,694-236,392-218,421-203,198-189,285-174,811-156,542-142,685-126,695-155,401-150,993-32,595-141,833-136,878-146,154-142,236-137,789-133,141-127,458-118,959-110,441-121,978-115,988-108,563-102,328-97,678-92,158-276-257-250-243-236-225-218-211-205-193-187-180-174-164-158-152-146-136-130-124-118-109-103-96-91-83-78-73-69-61-56-52-49-39-35-24
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
177,622
178,249
178,854
179,500
178,767
179,157
179,475
189,147
189,604
190,020
190,612
277,618
279,089
281,168
283,539
358,490
0
364,437
367,853
0
0
0
0
0
00000367,853364,4370358,490283,539281,168279,089277,618190,612190,020189,604189,147179,475179,157178,767179,500178,854178,249177,6220000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
125,465
125,613
125,740
126,331
127,097
169,881
176,954
177,933
178,249
178,854
179,500
179,096
146,150
179,475
189,147
189,604
190,019
190,611
277,618
279,089
281,168
283,539
358,490
361,689
364,437
367,853
370,904
374,129
377,718
380,651
383,208
383,208380,651377,718374,129370,904367,853364,437361,689358,490283,539281,168279,089277,618190,611190,019189,604189,147179,475146,150179,096179,500178,854178,249177,933176,954169,881127,097126,331125,740125,613125,465505050505050505050505050505050505050505050505050505050505050505050505050



5.3. Balance Sheets

Currency in USD. All numbers in thousands.